Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen

Contraception

Volumn 81, Issue 6, 2010, Pages 501-509

  Brucker, Cosima ^a   Hedon, Bernard ^b   The, Hok Sien ^c   Höschen, Kornelia ^d   Binder, Natascha ^d   Christoph, Annette ^d  

^a KLINIKUM NÜRNBERG   (Germany)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

24 4 day regimen; Antiandrogenic; Chlormadinone acetate; Combined oral contraceptive; Cycle control; Low dose ethinylestradiol; Oral contraception; Pearl Index

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ABDOMINAL PAIN; ACNE; ADULT; ARTICLE; ASCITES; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; COMEDO; CONFIDENCE INTERVAL; DEPRESSION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ESOPHAGUS VARICES BLEEDING; FATIGUE; FEMALE; HUMAN; IRRITABILITY; LIBIDO; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; METRORRHAGIA; MULTICENTER STUDY; NAUSEA; OVARY CYST; PAPULE; PHASE 3 CLINICAL TRIAL; PREGNANCY; PUSTULE; SEBORRHEA; SIDE EFFECT; SPOTTING; VAGINA DISCHARGE; VEIN THROMBOSIS; VOMITING; WELLBEING;

ACNE VULGARIS; ADOLESCENT; ADULT; BODY WEIGHT; CHLORMADINONE ACETATE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; DYSMENORRHEA; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIBIDO; MENSTRUAL CYCLE; OVULATION INHIBITION; TIME FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 77952110038     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.01.011     Document Type: Article

References (51)

1. Combined oral contraceptives. A statement by the committee on safety of drugs. Br Med J 2 (1970) 231-232
2. Jeffcoate T.N. R.C.O.G. statement on oral contraceptives. Br Med J 2 (1970) 293
3. Birkhauser M., Braendle W., Breckwoldt M., Keller P.J., Kuhl H., and Runnebaum B. [Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998]. Gynakol Geburtshilfliche Rundsch 38 (1998) 164-165
4. Birkhauser M., Braendle W., Breckwoldt M., Keller P.J., Kuhl H., and Runnebaum B. [Recommendations for oral contraception. 24th meeting of the "Zurich Discussion Circle"]. Gynakol Geburtshilfliche Rundsch 40 (2000) 172-175
5. Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
6. ®). Results of a post-marketing surveillance study. Clin Drug Invest 22 (2002) 221-231
7. Plewig G., Cunliffe W., Binder N., and Höschen K. Efficacy of an oral contraceptive containing ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg (EE/CMA; Belara®) in moderate acne resolution: a randomised, double-blind, placebo-controlled phase III trial. Contraception. 80 1 (2009) 25-33
8. Schramm G., and Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 67 (2003) 305-312
9. Winkler U., Daume E., Sudik R., et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care 4 (1999) 145-154
10. Worret I., Arp W., Zahradnik H., Andreas J., and Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203 (2001) 38-44
11. Zahradnik H., Goldberg J., and Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57 (1998) 103-109
12. Zahradnik H.P., and Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 77 (2008) 337-343
13. Schramm G., and Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 76 (2007) 84-90
14. Gallo M., Nanda K., Grimes D., and Schulz K. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev (2005) CD003989
15. Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72 (1999) 115-120
16. Potter L., Oakley D., de Leon-Wong E., and Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 28 (1996) 154-158
17. Pre-authorisation Evaluation of Medicines for Human Use. Guideline on clinical investigation of steroid contraceptives in women (2006), EMEA, London 1-6. http://www.ema.europa.eu/pdfs/human/ewp/051998en.pdf Available at:
18. Potter R.G. Application of the life table techniques to measurements of contraceptive effectiveness. Demography 3 (1966) 297-304
19. Belsey E.M., Machin D., and d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34 (1986) 253-260
20. Gerstman B.B., Gross T.P., Kennedy D.L., Bennett R.C., Tomita D.K., and Stadel B.V. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 81 (1991) 90-96
21. Wallach M., and Grimes D.A. Modern oral contraception. 1st ed (2000), Emron, Totowa, NJ
22. Sulak P.J., Scow R.D., Preece C., Riggs M.W., and Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
23. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
24. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., and Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
25. Archer D.F., Maheux R., DelConte A., and O'Brien F.B. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 181 (1999) 39-44
26. Cibula D., Karck U., Weidenhammer H.G., Kunz J., Alincic S., and Marr J. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg. Clin Drug Investig 26 (2006) 143-150
27. Endrikat J., Cronin M., Gerlinger C., Ruebig A., Schmidt W., and Dusterberg B. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception 64 (2001) 99-105
28. Rosenberg M.J., Waugh M.S., and Meehan T.E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 51 (1995) 283-288
29. Sabatini R., and Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 74 (2006) 220-223
30. Belsey E.M., and Carlson N. The description of menstrual bleeding patterns: towards fewer measures. Stat Med 10 (1991) 267-284
31. Gestodene, Study, Group, 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg. Eur J Contracept Reprod Health Care 4 Suppl. 2 (1999) 9-15
32. Gruber D.M., Huber J.C., Melis G.B., Stagg C., Parke S., and Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug. Treat Endocrinol 5 (2006) 115-121
33. Serfaty D., and Vree M.L. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care 3 (1998) 179-189
34. Winkler U.H., Ferguson H., and Mulders J.A. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 69 (2004) 469-476
35. Dando T.M., and Curran M.P. Low-dose ethinylestradiol/levonorgestrel. Drugs 65 (2005) 2299-2306 discussion 307-8
36. Godsland I.F., Winkler U., Lidegaard O., and Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 60 (2000) 721-869
37. Tchaikovski S., Tans G., and Rosing J. Venous thrombosis and oral contraceptives: current status. Women's Health 2 (2006) 761-772
38. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344 (2001) 1527-1535
39. Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception 55 (1997) 219-224
40. Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65 (2002) 215-221
41. Gaspard U., Endrikat J., Desager J.P., Buicu C., Gerlinger C., and Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69 (2004) 271-278
42. Wysocki. A survey of American women regarding the use of oral contraceptives and weight gain [abstract]. Int J Gynecol Obstet 70 (2000) 114
43. van de Weijer P. What women want and what their doctors need - how do women evaluate the quality of contraceptive methods and products introduced by their gynaecologist? A different perspective. Eur J Contracept Reprod Health Care 10 Suppl 1 (2005) 2-6
44. Sanders S., Graham C., Bass J., and Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64 (2001) 51-58
45. Mall-Haefeli M. Die Wirkung der Androgene auf das Zyklusgeschehen. In: Loch E.G., and Schramm G. (Eds). Chlormadinonacetat bei Androgenisierungserscheinungen (1995), Stuttgart, Schattauer 42-55
46. Lucky A., Biro F., Huster G., Leach A., Morrison J., and Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 130 (1994) 308-314
47. Kligman A. Postadolescent acne in women. Cutis 48 (1991) 75-77
48. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A., and Garner S.E. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev (2007) CD004425
49. Sabatini R., Orsini G., Cagiano R., and Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 76 (2007) 342-347
50. Kuhl H. In: Loch E. (Ed). Chemie und Pharmakologie von Chlormadinonacetat Chlormadinonacetat bei Androgenisierungserscheinungen (1995), Stuttgart, Schattauer
51. Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492